These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25430078)

  • 1. Nintedanib: first global approval.
    McCormack PL
    Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
    Keating GM
    Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
    Shiratori T; Tanaka H; Tabe C; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Takanashi S; Tasaka S
    Thorac Cancer; 2020 Jun; 11(6):1720-1723. PubMed ID: 32285615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
    Dimitroulis IA
    Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
    Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
    Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib: First Global Approval.
    Syed YY
    Drugs; 2018 Jul; 78(10):1057-1062. PubMed ID: 29943374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
    Noonan S; Man Wong K; Jimeno A
    Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Cottin V
    Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
    Ballester B; Milara J; Cortijo J
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib in idiopathic pulmonary fibrosis.
    Woodcock HV; Maher TM
    Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis.
    Kai Y; Matsuda M; Fukuoka A; Hontsu S; Yamauchi M; Yoshikawa M; Muro S
    Thorac Cancer; 2021 May; 12(9):1457-1460. PubMed ID: 33742758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib: from discovery to the clinic.
    Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
    J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
    Novello S; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Barrueco J; Gaschler-Markefski B; Griebsch I; Palmer M; Reck M;
    Eur J Cancer; 2015 Feb; 51(3):317-26. PubMed ID: 25534294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
    Bonella F; Stowasser S; Wollin L
    Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.